vs

Side-by-side financial comparison of AMES NATIONAL CORP (ATLO) and GYRE THERAPEUTICS, INC. (GYRE). Click either name above to swap in a different company.

GYRE THERAPEUTICS, INC. is the larger business by last-quarter revenue ($37.2M vs $18.7M, roughly 2.0× AMES NATIONAL CORP). AMES NATIONAL CORP runs the higher net margin — 34.9% vs -3.7%, a 38.5% gap on every dollar of revenue. On growth, GYRE THERAPEUTICS, INC. posted the faster year-over-year revenue change (33.4% vs 26.7%). AMES NATIONAL CORP produced more free cash flow last quarter ($20.7M vs $-5.8M). Over the past eight quarters, AMES NATIONAL CORP's revenue compounded faster (19.5% CAGR vs 17.0%).

Ames National Corp is a U.S. financial holding company based in Iowa. It operates multiple community banking subsidiaries, offering retail and commercial financial services including deposit accounts, personal and business loans, mortgages, and wealth management, primarily serving consumers and SMEs across central Iowa.

GYRE Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing novel targeted therapies for hard-to-treat hematologic malignancies and solid tumors. It focuses on precision oncology to address unmet patient needs, with operations primarily based in North America.

ATLO vs GYRE — Head-to-Head

Bigger by revenue
GYRE
GYRE
2.0× larger
GYRE
$37.2M
$18.7M
ATLO
Growing faster (revenue YoY)
GYRE
GYRE
+6.8% gap
GYRE
33.4%
26.7%
ATLO
Higher net margin
ATLO
ATLO
38.5% more per $
ATLO
34.9%
-3.7%
GYRE
More free cash flow
ATLO
ATLO
$26.5M more FCF
ATLO
$20.7M
$-5.8M
GYRE
Faster 2-yr revenue CAGR
ATLO
ATLO
Annualised
ATLO
19.5%
17.0%
GYRE

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
ATLO
ATLO
GYRE
GYRE
Revenue
$18.7M
$37.2M
Net Profit
$6.5M
$-1.4M
Gross Margin
95.3%
Operating Margin
44.3%
0.3%
Net Margin
34.9%
-3.7%
Revenue YoY
26.7%
33.4%
Net Profit YoY
85.4%
-340.1%
EPS (diluted)
$-0.01

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ATLO
ATLO
GYRE
GYRE
Q4 25
$18.7M
$37.2M
Q3 25
$16.6M
$30.6M
Q2 25
$16.1M
$26.8M
Q1 25
$15.5M
$22.1M
Q4 24
$14.7M
$27.9M
Q3 24
$13.5M
$25.5M
Q2 24
$13.5M
$25.2M
Q1 24
$13.1M
$27.2M
Net Profit
ATLO
ATLO
GYRE
GYRE
Q4 25
$6.5M
$-1.4M
Q3 25
$4.6M
$5.9M
Q2 25
$4.5M
$1.6M
Q1 25
$3.4M
$3.7M
Q4 24
$3.5M
$569.0K
Q3 24
$2.2M
$2.9M
Q2 24
$2.2M
$4.5M
Q1 24
$2.3M
$9.9M
Gross Margin
ATLO
ATLO
GYRE
GYRE
Q4 25
95.3%
Q3 25
94.7%
Q2 25
95.7%
Q1 25
95.9%
Q4 24
95.8%
Q3 24
96.2%
Q2 24
96.9%
Q1 24
96.4%
Operating Margin
ATLO
ATLO
GYRE
GYRE
Q4 25
44.3%
0.3%
Q3 25
34.5%
22.7%
Q2 25
35.0%
8.1%
Q1 25
27.4%
10.3%
Q4 24
29.4%
2.4%
Q3 24
19.4%
16.6%
Q2 24
19.0%
12.7%
Q1 24
20.8%
29.7%
Net Margin
ATLO
ATLO
GYRE
GYRE
Q4 25
34.9%
-3.7%
Q3 25
27.5%
19.4%
Q2 25
28.0%
5.9%
Q1 25
22.3%
16.9%
Q4 24
23.8%
2.0%
Q3 24
16.4%
11.2%
Q2 24
16.2%
18.0%
Q1 24
17.6%
36.6%
EPS (diluted)
ATLO
ATLO
GYRE
GYRE
Q4 25
$-0.01
Q3 25
$0.03
Q2 25
$0.00
Q1 25
$0.00
Q4 24
$0.00
Q3 24
$0.01
Q2 24
$0.01
Q1 24
$0.03

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ATLO
ATLO
GYRE
GYRE
Cash + ST InvestmentsLiquidity on hand
$126.8M
$52.4M
Total DebtLower is stronger
$18.4M
Stockholders' EquityBook value
$207.9M
$106.0M
Total Assets
$2.1B
$166.1M
Debt / EquityLower = less leverage
0.09×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ATLO
ATLO
GYRE
GYRE
Q4 25
$126.8M
$52.4M
Q3 25
$108.2M
$60.0M
Q2 25
$95.2M
$54.4M
Q1 25
$163.4M
$29.9M
Q4 24
$101.2M
$26.7M
Q3 24
$59.0M
$25.1M
Q2 24
$63.4M
$25.1M
Q1 24
$111.4M
$37.4M
Total Debt
ATLO
ATLO
GYRE
GYRE
Q4 25
$18.4M
Q3 25
Q2 25
Q1 25
Q4 24
$20.0M
Q3 24
Q2 24
Q1 24
Stockholders' Equity
ATLO
ATLO
GYRE
GYRE
Q4 25
$207.9M
$106.0M
Q3 25
$200.6M
$101.9M
Q2 25
$193.0M
$92.0M
Q1 25
$183.1M
$68.1M
Q4 24
$174.7M
$63.3M
Q3 24
$183.4M
$63.2M
Q2 24
$167.1M
$60.4M
Q1 24
$165.5M
$56.6M
Total Assets
ATLO
ATLO
GYRE
GYRE
Q4 25
$2.1B
$166.1M
Q3 25
$2.1B
$159.4M
Q2 25
$2.1B
$152.6M
Q1 25
$2.2B
$129.8M
Q4 24
$2.1B
$125.4M
Q3 24
$2.1B
$125.2M
Q2 24
$2.1B
$120.9M
Q1 24
$2.2B
$122.0M
Debt / Equity
ATLO
ATLO
GYRE
GYRE
Q4 25
0.09×
Q3 25
Q2 25
Q1 25
Q4 24
0.11×
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ATLO
ATLO
GYRE
GYRE
Operating Cash FlowLast quarter
$21.3M
$-5.6M
Free Cash FlowOCF − Capex
$20.7M
$-5.8M
FCF MarginFCF / Revenue
110.8%
-15.5%
Capex IntensityCapex / Revenue
3.4%
0.4%
Cash ConversionOCF / Net Profit
3.28×
TTM Free Cash FlowTrailing 4 quarters
$34.2M
$-180.0K

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ATLO
ATLO
GYRE
GYRE
Q4 25
$21.3M
$-5.6M
Q3 25
$2.8M
$4.7M
Q2 25
$4.0M
$2.1M
Q1 25
$7.1M
$-129.0K
Q4 24
$14.3M
$-2.8M
Q3 24
$3.1M
$1.7M
Q2 24
$3.9M
$-5.5M
Q1 24
$1.4M
$2.9M
Free Cash Flow
ATLO
ATLO
GYRE
GYRE
Q4 25
$20.7M
$-5.8M
Q3 25
$2.6M
$4.0M
Q2 25
$3.9M
$1.8M
Q1 25
$6.9M
$-251.0K
Q4 24
$14.0M
$-2.8M
Q3 24
$3.0M
$1.0M
Q2 24
$3.8M
$-6.9M
Q1 24
$1.3M
$2.7M
FCF Margin
ATLO
ATLO
GYRE
GYRE
Q4 25
110.8%
-15.5%
Q3 25
16.0%
13.1%
Q2 25
24.2%
6.8%
Q1 25
44.8%
-1.1%
Q4 24
94.9%
-10.1%
Q3 24
22.5%
4.1%
Q2 24
28.1%
-27.5%
Q1 24
10.0%
9.8%
Capex Intensity
ATLO
ATLO
GYRE
GYRE
Q4 25
3.4%
0.4%
Q3 25
0.6%
2.2%
Q2 25
0.7%
1.0%
Q1 25
1.3%
0.6%
Q4 24
2.0%
0.2%
Q3 24
0.5%
2.7%
Q2 24
0.7%
5.8%
Q1 24
0.5%
0.9%
Cash Conversion
ATLO
ATLO
GYRE
GYRE
Q4 25
3.28×
Q3 25
0.60×
0.79×
Q2 25
0.89×
1.32×
Q1 25
2.07×
-0.03×
Q4 24
4.07×
-4.85×
Q3 24
1.40×
0.60×
Q2 24
1.78×
-1.21×
Q1 24
0.59×
0.29×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons